A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

Effective targeting of primitive AML CD34+cells by the second-generation proteasome inhibitor carfilzomib

(2015) Lieke H. van der Helm et al.   BRITISH JOURNAL OF HAEMATOLOGY

Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4

(2014) Han Liu et al.   CANCER CELL

Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview

(2014) Andrzej J. Jakubowiak   CANCER TREATMENT REVIEWS

Proteasome inhibitors in the treatment of multiple myeloma

(2013) Ali McBride et al.   Expert Review of Anticancer Therapy

Proteasome inhibitors in acute leukemia

(2013) Denise Niewerth et al.   Expert Review of Anticancer Therapy

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

(2012) Y. H. Messinger et al.   BLOOD

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium

(2010) Yoav Messinger et al.   PEDIATRIC BLOOD & CANCER

Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia

(2008) E. C. Attar et al.   CLINICAL CANCER RESEARCH